Literature DB >> 34508791

Rational HCC screening approaches for patients with NAFLD.

Amit G Singal1, Hashem B El-Serag2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of developing hepatocellular carcinoma (HCC), especially among those who have cirrhosis or advanced fibrosis, but 20-30% of cases of NAFLD-related HCC occur in the absence of advanced fibrosis. The prevalence of NAFLD-related HCC is increasing in most countries worldwide. There are few direct data to support or refute the efficacy or effectiveness of HCC surveillance in NAFLD or to guide its application. We use evidence on surveillance in other conditions and studies on the clinical course of patients with NAFLD to arrive at recommendations for rational approaches to HCC surveillance in this growing cohort of patients. We also outline gaps in research and practice, including opportunities to advance the field. Published by Elsevier B.V.

Entities:  

Keywords:  biomarkers; cirrhosis; fatty liver; guidelines; liver cancer; metabolic dysfunction; surveillance

Mesh:

Year:  2021        PMID: 34508791      PMCID: PMC8688224          DOI: 10.1016/j.jhep.2021.08.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  53 in total

1.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

2.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Vincent Wai-Sun Wong; Marlen Castellanos; Rocio Aller-de la Fuente; Mayada Metwally; Mohammed Eslam; Licet Gonzalez-Fabian; María Alvarez-Quiñones Sanz; Antonio Felix Conde-Martin; Bastiaan De Boer; Duncan McLeod; Anthony Wing Hung Chan; Naga Chalasani; Jacob George; Leon A Adams; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

3.  Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.

Authors:  Valentina Santi; Franco Trevisani; Annagiulia Gramenzi; Alice Grignaschi; Federica Mirici-Cappa; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Fabio Farinati; Marco Zoli; Edoardo Giovanni Giannini; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Mauro Bernardi
Journal:  J Hepatol       Date:  2010-04-27       Impact factor: 25.083

Review 4.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

5.  Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.

Authors:  Benjamin Cadier; Julie Bulsei; Pierre Nahon; Olivier Seror; Alexis Laurent; Isabelle Rosa; Richard Layese; Charlotte Costentin; Carole Cagnot; Isabelle Durand-Zaleski; Karine Chevreul
Journal:  Hepatology       Date:  2017-02-08       Impact factor: 17.425

6.  Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.

Authors:  Karin L Andersson; Joshua A Salomon; Sue J Goldie; Raymond T Chung
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

7.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

8.  Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.

Authors:  Yamini Natarajan; Jennifer R Kramer; Xian Yu; Liang Li; Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2020-10       Impact factor: 17.425

9.  Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Authors:  Ramy Younes; Gian Paolo Caviglia; Olivier Govaere; Chiara Rosso; Angelo Armandi; Tiziana Sanavia; Grazia Pennisi; Antonio Liguori; Paolo Francione; Rocío Gallego-Durán; Javier Ampuero; Maria J Garcia Blanco; Rocio Aller; Dina Tiniakos; Alastair Burt; Ezio David; Fabio M Vecchio; Marco Maggioni; Daniela Cabibi; María Jesús Pareja; Marco Y W Zaki; Antonio Grieco; Anna L Fracanzani; Luca Valenti; Luca Miele; Piero Fariselli; Salvatore Petta; Manuel Romero-Gomez; Quentin M Anstee; Elisabetta Bugianesi
Journal:  J Hepatol       Date:  2021-06-04       Impact factor: 25.083

10.  Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012.

Authors:  Prabhu P Gounder; Lisa R Bulkow; Martin I Meltzer; Michael G Bruce; Thomas W Hennessy; Mary Snowball; Philip R Spradling; Bishwa B Adhikari; Brian J McMahon
Journal:  Int J Circumpolar Health       Date:  2016-05-18       Impact factor: 1.228

View more
  10 in total

1.  Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC).

Authors:  Jinna Chu; George Cholankeril; Xian Yu; Abbas Rana; Yamini Natarajan; Hashem B El-Serag; Jennifer Kramer; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2022-06-27       Impact factor: 3.487

Review 2.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 3.  Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma.

Authors:  Norberto C Chavez-Tapia; Sofía Murúa-Beltrán Gall; Ana Luisa Ordoñez-Vázquez; Natalia Nuño-Lambarri; Paulina Vidal-Cevallos; Misael Uribe
Journal:  J Hepatocell Carcinoma       Date:  2022-07-05

4.  Insights on the Risk of Hepatocellular Carcinoma in PatientsWith Nonalcoholic Steatohepatitis.

Authors:  Amit Singal; Willis C
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-01

5.  Multivariable-adjusted trends in mortality due to alcoholic liver disease among adults in the United States, from 1999-2017.

Authors:  Emily Ryu; Harry H Xia; Grace L Guo; Lanjing Zhang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

6.  DETECT: Development of Technologies for Early HCC Detection.

Authors:  Jihane N Benhammou; Nicole E Rich; George Cholankeril; Peng Zhang; Weihua Zeng; Shuyun Rao; Nabihah Tayob
Journal:  Gastroenterology       Date:  2022-03-23       Impact factor: 33.883

Review 7.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

8.  Identify Functional lncRNAs in Nonalcoholic Fatty Liver Disease by Constructing a ceRNA Network.

Authors:  Wei Xue; Jia Zhang; Yali Zhu; Wenxiang Huang
Journal:  ACS Omega       Date:  2022-06-22

Review 9.  Gastrointestinal and Liver Complications in Patients with Diabetes Mellitus-A Review of the Literature.

Authors:  Ruxandra Mare; Ioan Sporea
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

10.  Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease.

Authors:  Gian Paolo Caviglia; Aurora Nicolosi; Maria Lorena Abate; Patrizia Carucci; Chiara Rosso; Emanuela Rolle; Angelo Armandi; Serena Aneli; Antonella Olivero; Alessandra Risso; Davide Giuseppe Ribaldone; Christian Fermer; Giorgio Maria Saracco; Silvia Gaia; Elisabetta Bugianesi
Journal:  Curr Oncol       Date:  2022-07-31       Impact factor: 3.109

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.